Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers

On November 5, 2026 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported it will present important new Signatera data at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place November 4–8 in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immune checkpoint inhibitors (ICIs) have transformed treatment for many metastatic cancers, and some patients achieve durable disease control.1 However, it remains challenging for clinicians to determine how long to continue therapy, since imaging alone is prone to error and cannot show whether disease has cleared at the molecular level.2,3 As a result, treatment duration remains an open question, particularly for patients who achieve a durable clinical response.

A real-world analysis at SITC (Free SITC Whitepaper) studied outcomes of 424 patients treated with first-line immunotherapy across stage IV melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). The Signatera test was used to identify complete molecular responders (CMRs), defined as patients with two consecutive negative results. Findings showed:

Improved survival in Signatera MRD-negative patients: CMRs had a 36-month overall survival (OS) of 93.2% vs. 77.9% in all other patients (HR 0.24; P=0.0003).
Favorable survival across tumor types: At 36 months, OS in CMRs ranged from 83.1% (NSCLC) to 100% (MSI-H CRC).
No significant survival difference with early ICI discontinuation: OS for CMRs who remained on IO was 93.5% vs. those who stopped (89.4%) (P=0.42).
"For patients with metastatic cancer who achieve a durable response, deciding how long to continue immunotherapy is one of the most difficult clinical decisions," said Meghan J. Mooradian, MD, Cutaneous Medical Oncology, Mass General Brigham Cancer Institute, and lead author of the study. "Because imaging alone may not fully capture whether disease has been completely cleared, our findings support further investigation of molecular response as a biomarker to help personalize treatment duration and identify patients who may discontinue therapy early."

"Melanoma, kidney, lung, and colorectal cancers differ biologically, yet sustained Signatera negativity was associated with favorable survival in each," said Alexey Aleshin, MD, Corporate Chief Medical Officer and General Manager, Oncology, Natera. "These data support the role of Signatera in identifying exceptional ICI responders who may be able to de-escalate treatment."

References

Wolchok JD, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 2025;392:11-22.
Steimle AK, et al. Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma. Cancers 2026;18(18):3032.
Anagnostou V, et al. Immuno-oncology trial endpoints: Capturing clinically meaningful activity. Clin Cancer Res 2017;23(17):4959-69.

(Press release, Natera, NOV 5, 2026, View Source [SID1234674361])

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

On November 5, 2026 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported recent business highlights and financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST," said Andrew Robbins, Cogent’s President and Chief Executive Officer. "In parallel, our team is preparing for potential approvals in NonAdvanced and Advanced Systemic Mastocytosis and we expect to file INDs for our JAK2 and KRAS pipeline programs this quarter. Backed by a strong balance sheet and a world-class team, we are well positioned to continue our vision of creating best-in-class therapies for patients fighting rare, mutationally driven diseases."

Business Highlights

•
Plan to present multiple posters featuring bezuclastinib at the 68th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) being held December 12-15, 2026, in New Orleans. Featured results will highlight more detailed analyses from the SUMMIT trial of bezuclastinib’s effects on skin and neurocognitive symptoms, longer term pathobiology follow-up and an MS2D2 symptomatic comparison of symptom burden in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients before and after bezuclastinib treatment with that of the general population. Included in these presentations will be the first look at clinical results from the SUMMIT sub-study, investigating the patient benefit of switching from avapritinib to bezuclastinib.
•
Announced the initiation of a single-arm, 40 patient extension cohort of the PEAK trial investigating the safety and efficacy of bezuclastinib in combination with sunitinib in first-line GIST patients. This cohort is designed to prospectively measure ORR and PFS in patients with either exon 9 or exon 11 primary mutations.
•
Announced the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM).

Anticipated Upcoming Milestones

•
Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026
•
Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026
•
Potential FDA approval of bezuclastinib in AdvSM – PDUFA date of June 29, 2027
•
Investigational New Drug (IND) applications to be submitted for CGT1815, Cogent’s novel, selective pan-KRAS(ON) inhibitor, and CGT1145, Cogent’s novel, selective JAK2 V617F inhibitor in Q4 2026
•
Complete dose escalation for CGT4255, Cogent’s CNS-penetrant, selective mutant ErbB2 inhibitor
Upcoming Investor Conferences

•
Guggenheim Healthcare Innovation Conference on November 10 at 7:30 am ET
•
UBS Global Biopharma Conference on November 17 at 12:00 pm GMT (7:00 am ET)
•
Jefferies Global Healthcare Conference on November 17 at 5:00 pm GMT (12:00 pm ET)
•
Piper Sandler Healthcare Conference on December 1 at 11:00 am ET
The live webcasts can be accessed on the Investors & Media page of Cogent’s website at investors.cogentbio.com/events. A replay will be available approximately two hours after completion of each event and will be archived for up to 30 days.

Third Quarter 2026 Financial Results

Cash Position: As of September 30, 2026, cash, cash equivalents and marketable securities were $791.1 million, as compared to $792.3 million as of June 30, 2026. The company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib.

R&D Expenses: Research and development expenses were $75.1 million for the third quarter of 2026 as compared to $69.0 million for the third quarter of 2025. The increase was primarily due to costs incurred to support our on-going SUMMIT, PEAK and APEX clinical trials and to the continued progression of our early stage, preclinical and discovery programs. R&D expenses include non-cash stock compensation expense of $7.5 million for the third quarter of 2026 compared to $5.4 million for the third quarter of 2025.

G&A Expenses: General and administrative expenses were $42.1 million for the third quarter of 2026 as compared to $14.4 million for the third quarter of 2025. The increase was primarily due to continued investments in commercial readiness, including personnel and infrastructure to support the potential launch of bezuclastinib, as well as overall organizational growth. G&A expenses include non-cash stock compensation expense of $9.4 million for the third quarter of 2026 compared to $5.2 million for the third quarter of 2025.

Net Loss: Net loss was $111.4 million for the third quarter of 2026 as compared to a net loss of $80.9 million for the same period of 2025.

(Press release, Cogent Biosciences, NOV 5, 2026, View Source [SID1234674302])

Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

On November 5, 2026 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, reported business highlights and financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "The GFORCE-1 results reinforce our view that targeting NEK7 at the top of the NLRP3 signaling cascade could address a broader set of disease drivers than targeting individual downstream cytokines. Our planned Phase 2 studies in coronary artery disease (CAD), gout, and hidradenitis suppurativa, conditions with major unmet needs, are intended to deepen our understanding of the therapeutic potential of NEK7 degradation. In CAD, our innovative study design integrates molecular and imaging-based readouts to explore how MRT-8102’s broad biological activity translates into changes in coronary plaque biology, to inform patient selection and design for an efficient future Phase 3 study."

Dr. Warmuth continued: "We are particularly excited about the opportunity in gout, where there is a substantial unmet need for effective flare prevention that is well tolerated with prolonged use. With the emergence of next-generation urate-lowering drugs and their propensity to induce flares in the first 6 to 12 months of use, we believe the need for a well-tolerated, non-immunosuppressive flare prevention treatment will only increase. We expect initial data from our Phase 2 gout study in H2 2027. Across the broader pipeline, we are pursuing a focused development strategy for MRT-2359 through MODeFIRe-1, evaluating its potential in combination with apalutamide in mCRPC patients with AR mutations. We have shown previously that degradation of GSPT1 dampens MYC signaling in CRPC, a pathway we believe is moving to center stage for new treatment options in CRPC. We look forward to a data update from this Phase 2 study in 2027, as well as a final data update from our completed Phase 1/2 study of MRT-2359 in combination with enzalutamide by year-end. Novartis’s advancement of MRT-6160 (DDY391) into Phase 2 studies in Sjögren’s disease and psoriatic arthritis expands the evaluation of VAV1 degradation across immune-mediated diseases and brings additional non-dilutive funding to Monte Rosa. With our balance sheet expected to support operations into 2029, we are well positioned to pursue these opportunities while maintaining a disciplined focus on generating clinical evidence and advancing our pipeline."

RECENT HIGHLIGHTS

MRT-8102, NEK7-directed MGD for inflammatory diseases driven by NEK7/NLRP3 and IL-1

•
In October, Monte Rosa reported positive results from GFORCE-1 (NCT07119125), a Phase 1 study of MRT-8102 in 108 obese subjects with elevated cardiovascular disease risk. Across all three dose levels, MRT-8102 achieved median NEK7 degradation of approximately 80% to 90%. MRT-8102 also resulted in substantial reductions of IL-1β as well as HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs) linked to pathogenic biology within atherosclerotic plaques and vessel walls. MRT-8102 was well tolerated, with no serious adverse events, adverse event rates similar to placebo, and no evidence of increased infection risk.
•
With dose selection informed by the GFORCE-1 data, Monte Rosa plans to initiate three Phase 2 studies of MRT-8102:
o
GEMINI-1, a Phase 2 study in patients with gout, is expected to initiate in Q4 2026. The study will evaluate prevention of flare recurrence following management of acute flares, with initial data expected in H2 2027.
o
GFORCE-2, a focused Phase 2b study in patients with stable coronary artery disease and residual inflammation, is expected to initiate in H1 2027. The study is expected to evaluate imaging-based coronary artery plaque assessment, such as fat attenuation index (FAI), along with NLRP3 genetics and molecular drivers of local disease pathogenesis and systemic inflammation, to inform the design of an innovative and efficient Phase 3 study focused on the most disease-modifiable patient population.
o
GALAXY-1, a Phase 2 study in patients with moderate to severe hidradenitis suppurativa, is expected to initiate in H1 2027.
•
Due to prioritization of the MRT-8102 Phase 2 study initiations, Investigational New Drug (IND) submission for the next-generation NEK7 MGD is now anticipated in 2027.

MRT-2359, GSPT1-directed MGD for mCRPC

•
In August, Monte Rosa dosed the first patient in MODeFIRe-1 (NCT07745361), a Phase 2 study of MRT-2359 in combination with apalutamide in AR-mutant mCRPC patients who received prior treatment with a second-generation AR inhibitor. The study will enroll up to 25 patients, with MRT-2359 administered orally at 0.5 mg on a 21 days on, 7 days off schedule. Endpoints include PSA response, RECIST response, duration of response, radiographic progression-free survival, PSA progression-free survival, and safety. Monte Rosa has a clinical supply agreement with Johnson & Johnson to support the study.
•
Enrollment in the initial Phase 1/2 study expansion arm, in patients with mCRPC, has been completed. A total of 6 patients with AR mutations were enrolled and treated with MRT-2359 in combination with enzalutamide. Monte Rosa plans to provide an update on this patient subset by the end of the year. Interim data were presented at the ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU) in February.

MRT-6160 (DDY391), VAV1-directed MGD for immune-mediated conditions

•
In September, Monte Rosa announced achievement of a milestone associated with its collaborator Novartis initiating a global Phase 2a/b randomized, double-blind, placebo-controlled study (NCT07737743), evaluating the efficacy, safety, and tolerability of up to 52 weeks of treatment with MRT-6160 (DDY391) in participants with Sjögren’s disease. The first patient visit triggered a $50 million milestone payment to Monte Rosa.
•
In October, Monte Rosa announced achievement of an additional milestone associated with Novartis initiating a second Phase 2 study of MRT-6160 (DDY391) in participants with active moderate to severe psoriatic arthritis (PsA). The Phase 2a/b randomized, double-blind, placebo-controlled, multicenter study (NCT07801495) will evaluate the efficacy, safety, tolerability, and dose-response relationship of MRT-6160 (DDY391). The first patient visit triggered a $37.5 million milestone payment to Monte Rosa.
•
The Sjögren’s and PsA studies are the first two of several studies expected for MRT-6160 (DDY391). Under its global exclusive development and commercialization license agreement with Novartis, Monte Rosa is eligible for additional Phase 2 study initiation milestone payments.

CDK2 and Cyclin E1-directed MGD programs for solid tumors

•
Monte Rosa expects to submit IND applications for its CDK2 and cyclin E1 (CCNE1)-directed MGD programs in 2027.

ANTICIPATED UPCOMING MILESTONES AND DEVELOPMENT PRIORITIES

Immunology and inflammation programs

•
Initiate GEMINI-1 Phase 2 study of MRT-8102 in gout in Q4 2026, with initial data expected in H2 2027.
•
Initiate GFORCE-2 Phase 2b study of MRT-8102 in stable coronary artery disease in H1 2027.
•
Initiate GALAXY-1 Phase 2 study of MRT-8102 in moderate to severe hidradenitis suppurativa in H1 2027.
•
Monte Rosa expects its collaborator, Novartis, to initiate additional Phase 2 studies of MRT-6160 (DDY391) in immune-mediated diseases.

Oncology programs

•
Provide a clinical data update on the initial Phase 1/2 expansion arm exploring MRT-2359 in combination with enzalutamide in mCRPC by the end of 2026.
•
Provide a clinical data update on the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations in 2027.
•
Submit an IND application for a CDK2-directed MGD in 2027.
•
Submit an IND application for a CCNE1-directed MGD in 2027.

THIRD QUARTER 2026 FINANCIAL RESULTS

Collaboration Revenue: Collaboration revenue for the third quarter of 2026 was $54.4 million, compared to $12.8 million for the third quarter of 2025. The increase was primarily driven by recognition of collaboration revenue from the $50.0 million milestone triggered by the initiation of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with Sjögren’s disease. The $37.5 million milestone triggered by the initiation of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with psoriatic arthritis in October is not reflected in third quarter collaboration revenue as it was triggered after the end of the quarter. Collaboration revenue represents amounts earned from Monte Rosa’s collaboration and license agreements with Roche and Novartis.

Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2026 were $45.4 million, compared to $36.7 million for the third quarter of 2025. The increase was primarily driven by increased spending on development and discovery programs. R&D expenses included non-cash stock-based compensation of $3.3 million for the third quarter of 2026, compared to $2.5 million in the same period in 2025.

General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2026 were $10.9 million, compared to $9.1 million for the third quarter of 2025. G&A expenses included non-cash stock-based compensation of $3.0 million for the third quarter of 2026, compared to $1.9 million in the same period in 2025.

Net Income (Loss): Net income for the third quarter of 2026 was $3.1 million, compared to a net loss of $27.1 million for the third quarter of 2025.

Cash Position and Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026, were $582.6 million, compared to $626.0 million as of June 30, 2026. The decrease of $43.4 million was primarily due to operational use of cash. In September, Monte Rosa announced achievement of a $50 million milestone associated with the first patient visit of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with Sjögren’s disease. In October, Monte Rosa announced achievement of a $37.5 million milestone associated with the first patient visit of the Novartis Phase 2 study of MRT-6160 (DDY391) in participants with active moderate to severe psoriatic arthritis. Cash receipts from these milestones are not reflected in the September 30th cash balance as the payments had not yet been received as of that date. Monte Rosa expects that its cash, cash equivalents, restricted cash, and marketable securities will support operations into 2029.

(Press release, Monte Rosa Therapeutics, NOV 5, 2026, View Source [SID1234674318])

GENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate Update

On November 5, 2026 GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, reported its third quarter 2026 financial results1 and provides a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cash and Revenue

Cash position
As of September 30, 2026, the Company’s cash and cash equivalents amounted to €95.6 million compared with €113.8 million as of June 30, 2026, and €101.1 million as of December 31, 2025.

In 2026, cash consumption was primarily driven by research and development activities across our Acute-on-Chronic Liver Failure (ACLF) franchise programs, notably NTZ/G1090N, SRT-015, CLM-022 and VS-02 HE, as well as our GNS561 program in cholangiocarcinoma (CCA). Cash consumption was partially offset by two significant cash inflows during the first half of 2026: (i) the second €30.0 million tranche received under the royalty financing agreement and (ii) the receipt of the first commercial milestone from Ipsen totaling €17.0 million ($20.0 million), which had been recognized in 2025 and was received in cash in 2026.

Cash runway
We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its R&D pipeline and support general corporate purposes. Beyond this period, as sales of elafibranor increase, we expect related cash flows to become an increasingly important source of funding, with the objective of ultimately financing our operations and future development through cash generated by the business. This is based on current assumptions and programs and does not include exceptional events. In particular, this assumes (i) the continued commercial performance of Iqirvo (elafibranor) and resulting royalties, (ii) the expectation to receive significant commercial milestones under the Ipsen Agreement, (iii) maintaining operating expenses at levels broadly consistent with current expectations, (iv) the development of revenues from our diagnostic activities, and (v) the possibility to draw down, if needed, the third and final installment of the Royalty Financing agreement.

Revenue

Revenue Nine-months ended
(In € thousands) 30/09/2025 30/09/2026
Royalty revenue 12,596 36,308
Milestone revenue 26,556 0
Other revenue 81 125
Total 39,233 36,433
Royalty revenue

Virtually all royalty revenue is derived from worldwide sales of Ipsen’s Iqirvo2 (elafibranor) under the Ipsen Agreement. These are utilized to repay the Group’s Royalty Financing agreement. Year-over-year growth for the periods presented was 188%, reflecting accelerating U.S. sales and strong performance across Europe and other markets.

Milestone revenue

On May 20, 2025, GENFIT announced that Ipsen’s Iqirvo (elafibranor) was granted pricing and reimbursement in Italy for Primary Biliary Cholangitis (PBC), the third major European country to do so in addition to the UK and Germany. This third approval triggered a milestone payment of €26.5 million under GENFIT’s Licensing and Collaboration Agreement with Ipsen, due upon pricing and reimbursement of Iqirvo (elafibranor) in three major European markets.

Year-over-year revenue comparisons should consider the timing of milestone payments. Revenue for the nine months ended September 30, 2025 included a milestone payment, while no milestone revenue was recognized in the nine months ended September 30, 2026. Additional milestone revenue may however be recognized in future periods.

Corporate update

Elafibranor in cholestatic liver diseases

Primary Biliary Cholangitis (PBC) – Iqirvo net sales reached €109.4 million in Q3 2026, compared with €48.6 million in Q3 2025, representing 125.4% year-over-year growth at constant exchange rates (CER). For the first nine months of 2026, net sales reached €282.6 million, versus €107.4 million over the same period in 2025, representing 170.8% growth at CER.3 Iqirvo is leading growth within Rare Disease, Ipsen’s fastest-growing franchise. Earlier in July, Ipsen upgraded its peak sales estimates from €500 million to €1 billion in PBC. This revision followed Ipsen’s announcement on July 13, 20264, that the primary endpoint of alkaline phosphatase (ALP) normalization had been achieved in 85% of patients treated with Iqirvo (elafibranor), compared with 23% of patients receiving placebo at Week 52, in the Phase 3 ELSPIRE study.

Next steps: Following positive results of the ELSPIRE study, regulatory submission is underway for PBC label update. Ipsen intends to publish its full-year results and fourth-quarter sales on February 11, 2027.

Primary Sclerosing Cholangitis (PSC) – Phase 3 ELASCOPE study launched early 2026 is still ongoing. The market opportunity in PSC is estimated to be comparable in size to the second‑line PBC market. Subject to successful development and regulatory approval of elafibranor in this indication, GENFIT would be eligible to receive additional milestone payments as well as incremental double‑digit royalties.

Next steps: Data readout expected around 2031.
Non-invasive diagnostic technology in Metabolic dysfunction‑Associated SteatoHepatitis (MASH)
Medicare reimbursement for Labcorp’s NASHnext2 test (based on GENFIT’s NIS technology) became effective in August 2026 (under the Clinical Laboratory Fee Schedule) for patients meeting coverage criteria. GENFIT believes broader reimbursement by private payers, if obtained, could support accelerated adoption of its technology over time. Further market expansion could also be supported by a potential future In Vitro Diagnostics (IVD) launch, which may facilitate deployment across a wider range of healthcare settings.

In September, based on intention-to-diagnose data collected across key specialties, increasing disease prevalence, and a staged commercialization strategy spanning Laboratory Developed Tests (LDT) and IVD, IQVIA estimated that U.S. peak annual sales of products using GENFIT’s technology could exceed $1.5 billion by 2033, with annual testing volume in the U.S. reaching more than 7 million tests.5

GENFIT is engaging with stakeholders at AASLD The Liver Meeting 2026 (November 5-9) to raise awareness of the evolving evidence supporting non-invasive approaches to identifying patients with at-risk MASH, including its NIS Technology.

Next steps: GENFIT intends to outline its industrial strategy for the development and large-scale commercialization of an IVD kit based on its NIS Technology toward year-end. Subject to successful development, regulatory approval, partner execution and market adoption, GENFIT believes a potential commercial launch from 2028 could contribute to a meaningful acceleration in NIS-related revenues over time.
R&D pipeline

Nangibotide to be evaluated in Phase 2 in ACLF – In summer 2026, GENFIT acquired the nangibotide program, a differentiated late-stage asset targeting the TREM-1 pathway. Phase 2 development is supported by efficacy signals observed across three prior Phase 2 clinical trials in septic shock and Covid19, including statistically significant improvements in mortality and SOFA score in selected analyses, together with a favorable safety and tolerability profile across more than 400 exposed subjects.

Next steps: Nangibotide is expected to enter a Phase 2 study in ACLF by year-end, with data readout targeted in the second half of 2027.

Nitazoxanide to be evaluated in Phase 2 in ACLF – Positive Phase 1 data reported in early 2026 confirmed the favorable safety profile of NTZ and demonstrated multi‑modal biological activity, supporting its continued clinical development across the ACLF disease continuum. In March 2026, FDA granted Orphan Drug Designation for NTZ for the treatment of ACLF.

Next steps: The proof‑of‑concept study initiated in the third quarter of 2026 is expected to deliver data in mid-2027.

GNS561 to be evaluated in Phase 2 in combination, in KRAS mutated CCA – Encouraging preliminary data from the ongoing Phase 1b study evaluating GNS561 in combination with a MEK inhibitor in KRAS-mutated CCA were disclosed in December 2025 and June 2026, leading to the expansion of the study into additional cohorts.

Next steps: Additional Phase 1b data expected by year-end; Phase 2 initiation on track by year-end, with data readout targeted for the second half of 2027.

Research programs in ACLF and CCA – GENFIT is directing its capital and development resources towards the programs with the strongest translational rationale and clinical potential.

Next steps: Further details will be provided as and when these programs advance into clinical development.

(Press release, Genfit, NOV 5, 2026, https://ir.genfit.com/news-releases/news-release-details/genfit-reports-third-quarter-2026-financial-information-and [SID1234674346])

Pilatus Biosciences Presents New Preclinical Data at SITC 2026 Demonstrating Potential of PLT012 to Overcome Immunotherapy Resistance in Liver Cancer

On November 5, 2026 Pilatus Biosciences, a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, reported the presentation of new preclinical data supporting the therapeutic potential of PLT012, its investigational anti-CD36 monoclonal antibody, in overcoming acquired resistance to PD-1 immunotherapy in hepatocellular carcinoma (HCC) at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting, held November 4-8, 2026, in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research, conducted in collaboration with investigators at Zhongshan Hospital, Fudan University, identifies a previously underexplored mechanism of immunotherapy resistance in which sustained PD-1 treatment and selection lead to immunoediting-driven metabolic reprogramming in tumor cells, creating a lipid-rich, immunosuppressive tumor microenvironment. Increased expression of CD36, a key regulator of lipid uptake, was associated with impaired antitumor immune responses and acquired treatment resistance.

In preclinical models of PD-1-resistant liver cancer, PLT012 treatment counteracted CD36-associated immunosuppressive effects within the tumor microenvironment and significantly inhibited tumor growth, supporting CD36 inhibition as a potential therapeutic strategy for patients who develop resistance to existing checkpoint inhibitors.

"Acquired resistance to PD-1 immunotherapy remains a significant challenge in treating advanced liver cancer, with limited therapeutic options available once patients stop responding," said Yi-Ru Yu, Ph.D., Head of Biology, R&D, Pilatus Biosciences. "Our findings highlight the critical role of lipid metabolic reprogramming in acquired PD-1 resistance and demonstrate the potential of PLT012 to tackle lipid-mediated immunosuppression, with tumor growth inhibition observed in preclinical models. These results provide further mechanistic validation of our approach and reinforce the potential of PLT012 to address an important unmet need in liver cancer."

The study utilized a preclinical model of acquired PD-1 resistance, developed through three generations of consecutive anti-PD-1 treatment and selection, combined with multi-omic analyses to characterize changes in tumor metabolism and immune activity.

Key findings include:

Metabolic reprogramming drives treatment resistance: Acquired PD-1 resistance was associated with epigenetic and transcriptional changes that increased lipid metabolism in tumor cells, contributing to an immunosuppressive tumor microenvironment.
CD36 contributes to immune dysfunction: Increased CD36 expression on tumor-infiltrating immune cells was associated with reduced effector T-cell and natural killer cell activity, alongside increased immunosuppressive macrophage and neutrophil populations.
PLT012 demonstrates antitumor activity: Targeting CD36 with PLT012 mitigated lipid-associated immunosuppression and significantly inhibited tumor growth in preclinical models resistant to PD-1 treatment.
"These findings strengthen the scientific rationale for advancing PLT012 in HCC following prior immunotherapy," said George E. Peoples, M.D., Chief Medical Officer, Pilatus Biosciences. "Our planned Phase 1/2 development will prioritize monotherapy dose optimization and rational combination studies, supported by biomarker analyses. By linking CD36 target engagement and changes in the tumor immune microenvironment with clinical outcomes, we aim to establish preclinical-to-clinical concordance and determine whether the immune effects observed in our models translate into durable antitumor activity in patients."

Poster Presentation Details

Title: Immunoediting-Induced Lipid Metabolism Fosters Acquired PD-1 Resistance in Hepatocellular Carcinoma via CD36-Mediated Immune Suppression

Poster Number: 380

Conference: Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting

Date: November 7, 2026

Location: Phoenix Convention Center, Phoenix, Arizona

(Press release, Pilatus Biosciences, NOV 5, 2026, View Source [SID1234674362])